Health
PSMA-Directed Therapies and Diagnostics Expand Their Scope in Prostate Cancer – Targeted Oncology
With the emergence of therapies that target PSMA, a cell surface transmembrane protein that is overexpressed in most prostate cancer cells, particularly in castration-resistant…
The December 2020 approval of the first agent for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA)positive lesions in patients with prostate cancer, Gallium 68 PSMA-11 (Ga 68 PSMA-11), heralded an exciting new chapter in the diagnosis and treatment of metastatic castration-resistant prostate cancer (mCRPC). With the emergence of therapies that target PSMA, a cell surface transmembrane protein that is overexpressed in most prostate cancer cells, particularly…
-
Noosa News22 hours agoEnsure voices are heard – Proctor
-
Noosa News24 hours agoCity of Moreton Bay claims homeless people consented to having camps thrown away
-
Business19 hours agoUp 34% this year, can Challenger shares keep rising according to Macquarie?
-
General24 hours agoFederal politics live: Government says RBA rate cut decision about ‘pace, not direction’